Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 1;97(1):E161-E167.
doi: 10.1002/ccd.28986. Epub 2020 Jun 22.

A single healthcare experience with Impella RP

Nikoloz Shekiladze  1 , Jose F Condado  1 , Pratik B Sandesara  1 , Jeong Hwan Kim  1 , Chandan Devireddy  1 , Michael McDaniel  1 , Vasilis Babaliaros  1 , Habib Samady  1 , Gautam Kumar  1 , Wissam A Jaber  1
Affiliations

A single healthcare experience with Impella RP

Nikoloz Shekiladze et al. Catheter Cardiovasc Interv. .

Abstract

Objectives: To understand the predictors of survival and indications for Impella RP in a single healthcare experience.

Background: The Impella RP can be used to temporarily support patients with right ventricular (RV) dysfunction after left ventricular assist device (LVAD) placement or myocardial infarction (MI). However, recent postmarket approval data have raised concerns of higher than expected mortality with this device.

Methods: A retrospective chart review and analysis of all patients that underwent Impella RP placement in the Emory Healthcare system between January 2016 and December 2018 were performed. Patients were classified according to the indication.

Results: A total of 39 patients underwent Impella RP placement. Six patients were post-LVAD, 9 were implanted for massive pulmonary embolism with persistent shock, 8 for postcardiac surgery RV failure (non-LVAD), 11 for RV failure post-MI, and 5 for new or worsening nonischemic cardiomyopathy. The worst survival was noted in MI-related cardiogenic shock group and in patients who presented with cardiac arrest (3/12). All observed deaths were due to persistent refractory shock. There was no device related death. Survival improved during the last year of experience compared to the first 2 years.

Conclusion: This study supports the selective use of the Impella RP, with a higher than national reported survival rate (49% vs. 28.6%). Indication appears to be an important factor determining survival.

Keywords: Impella RP; hemodynamic circulatory support; right ventricular failure.

PubMed Disclaimer

References

REFERENCES

    1. Harjola VP, Mebazaa A, Celutkiene J, et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail. 2016;18(3):226-241.
    1. Spinar J, Parenica J, Vitovec J, et al. Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Crit Care. 2011;15(6):291.
    1. Konstam MA, Kiernan MS, Bernstein D, et al. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. Circulation. 2018;137(20):e578-e622.
    1. Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg. 2010;139(5):1316-1324.
    1. Sultan I, Kilic A, Kilic A. Short-term circulatory and right ventricle support in cardiogenic shock: extracorporeal membrane oxygenation, tandem heart, CentriMag, and Impella. Heart Fail Clin. 2018;14(4):579-583.

LinkOut - more resources